Chiusura precedente | 54,18 |
Aperto | 54,16 |
Denaro | 55,12 x 800 |
Lettera | 55,12 x 1100 |
Min-Max giorno | 53,75 - 56,85 |
Intervallo di 52 settimane | 27,65 - 133,82 |
Volume | |
Media Volume | 1.239.288 |
Capitalizzazione | 5,626B |
Beta (5 anni mensile) | 0,80 |
Rapporto PE (ttm) | N/D |
EPS (ttm) | -4,13 |
Prossima data utili | 02 nov 2022 - 07 nov 2022 |
Rendimento e dividendo (forward) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | 95,36 |
REDWOOD CITY, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH) along with leading academic institutions and pharmaceutical companies will present data demonstrating the advantages of using the Guardant360® liquid biopsy test for clinical decision-making in advanced lung cancer at the IASLC 2021 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer, September 8-14, 2021. “The new data adds further to the body of evidence
REDWOOD CITY, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating virtually in the upcoming Morgan Stanley Global Healthcare Conference. Guardant Health’s management is scheduled to participate in a fireside chat on Thursday, September 9 at 1:15 p.m. Pacific Time / 4:15 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors